Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on ... Roche has also reported Sutent-topping results with

Latest news

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... It’s another win for Merck in this treatment space over rival

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    In the KEYNOTE-042 trial, PD-1 inhibitor Keytruda (pembrolizumab) improved overall survival compared to platinum hemotherapy when given on its own to ‘all-comer’patients with locally advanced or metastatic ... It’s worth noting that rival PD-1

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    BMS is also partnered with Incyte on a trial of its PD-1 inhibitor Opdivo (nivolumab) with epacadostat, as is AstraZeneca with its PD-L1 blocker Imfinzi (durvalumab), so the blow ... That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... The EMA has kicked off its review of Sanofi and Regeneron’s immuno-oncology drug cemiplimab, which is aiming to become

  • Another Tecentriq win for Roche as Avastin combo boosts survival Another Tecentriq win for Roche as Avastin combo boosts survival

    The 1, 200 patient trial compared PD-L1 inhibitor Tecentriq with VEGF inhibitor Avastin as a combination as well as each drug individually on top of carboplatin and paclitaxel chemotherapy.

More from news
Approximately 3 fully matching, plus 156 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

  • Pharma deals during October 2014 Pharma deals during October 2014

    Medivation closed an exclusive worldwide licence with rights to CureTech's pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. ... The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics